We’re pleased to invite you to Drafts & Discoveries, a curated user group event bringing together scientists working at the forefront of targeted protein degradation and next-generation cell model development.
Hosted by EditCo and Promega, this event highlights how researchers are using engineered cell models to study protein dynamics, quantify degradation, and accelerate discovery in PROTAC and molecular glue pipelines.
Hear directly from scientists applying these approaches in real workflows, connect with fellow researchers in the field, and enjoy lunch, drinks, and raffle giveaways throughout the event.
📍 Location: Cambridge Innovation Center, Cambridge, MA
Address: 1 Broadway, 5th Floor, Cambridge, MA 02142
Room: Havana Lecture Hall
⏳ Limited capacity — registration required
Featured Talks
- Sam Hasson, Senior Director at Rgenta Therapeutics
Talk title: Genome Editing for Endogenous Analysis of Small Molecule Pre-mRNA Splicing Modulators
How engineered cell models and endogenous tagging strategies enable quantitative analysis of protein dynamics and small-molecule effects in functional genomics and drug discovery. -
Diogo Ferri Marques, Postdoctoral Associate at Broad Institute of MIT and Harvard
Talk title: Mapping Schizophrenia Risk in Human iPSC-Derived Neural Models: The SETD1A Story
How SETD1A loss reshapes chromatin across human neural development, revealing a time-dependent vulnerability window and partial pharmacologic rescue relevant to schizophrenia risk biology. - Nicole Curnutt, Ph.D. Candidate at Harvard University
Talk title: Casein kinase 1 alpha degrader DEG-77 targets TP53 WT gynecologic cancers with MDM4 dependence and altered SWI/SNF
CK1a is an emerging therapeutic target in oncology that can be accessed by molecular glue degraders such as lenalidomide and next-generation compounds like DEG-77. Investigations into common features shared by cell lines sensitive to CK1a degradation revealed that subtypes of ovarian and endometrial cancers characterized by loss of function in the SWItch/Sucrose Non-Fermenting chromatin remodeling complex rely on MDM4 to prevent p53 activation. CK1a degradation frees p53 from MDM4, allowing p53 to execute apoptosis and cell cycle arrest and leading to pronounced antiproliferative effects in models of these aggressive and difficult-to-treat cancers. - Andrew Zhang, Senior Strategic Collaborations Manager at Promega
Talk title: HiBiT: Unlocking biology in its native context
HiBiT has become an indispensable tool in drug discovery when studying changes in protein expression, especially in the field of targeted protein degradation. In these applications, endogenous expression is critical to get the most accurate view of protein dynamics. We will discuss applications of the HiBiT technology to targeted protein degradation applications and give a preview for a recent development for understanding cellular target engagement for challenging targets.
- Travis J. Maures, Co-Founder & Chief Scientific Officer at EditCo Bio
Talk title: Altering Is Easy, Engineering Is Hard
CRISPR has made genome editing routine, but reproducibility and genomic integrity remain key challenges for translational applications. We developed an automated, industrial-scale gene-editing platform that standardizes workflows across diverse cell types to reduce variability and improve edit quality.
By analyzing thousands of tracked editing reactions, the platform identifies conditions linked to structural genomic variations, including large deletions and rearrangements missed by conventional QC, and enables strategies to detect and mitigate them.
Together, this work advances genome editing from an empirical workflow toward a controlled engineering process.
Spaces are limited—sign up now!
Previous Event Highlights
It was great connecting with the genome engineering community at our Draughts & Discoveries event in Cambridge, UK.
Watch the video below to hear directly from attendees and see highlights from the event.
Reserve your spot by filling out the form below!